Compare TEVA & MDLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | MDLN |
|---|---|---|
| Founded | 1901 | 1966 |
| Country | Israel | United States |
| Employees | 32842 | 45000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.1B | 37.4B |
| IPO Year | N/A | N/A |
| Metric | TEVA | MDLN |
|---|---|---|
| Price | $30.81 | $38.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 23 |
| Target Price | $38.63 | ★ $50.48 |
| AVG Volume (30 Days) | 4.3M | ★ 6.9M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.88 |
| Revenue Next Year | $2.97 | $7.69 |
| P/E Ratio | ★ $28.19 | $658.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.99 | $32.82 |
| 52 Week High | $37.35 | $50.88 |
| Indicator | TEVA | MDLN |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 49.10 |
| Support Level | $30.59 | $38.08 |
| Resistance Level | $32.74 | $43.87 |
| Average True Range (ATR) | 0.97 | 1.62 |
| MACD | -0.19 | -0.37 |
| Stochastic Oscillator | 23.56 | 31.51 |
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Medline is the largest medical-surgical products and supply chain solutions provider in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.